20150331140159

Headquartered in Zurich as a subsidiary of Takeda Pharmaceutical Company Limited, Osaka, Japan, the company has a commercial presence covering more than 70 countries, with particular strength in Asia, North America, Europe and fast-growing emerging markets including Latin America, Russia-CIS and China. Areas of focus include cardiovascular and metabolic, oncology, respiratory and immunology, central nervous system, general medicine, and vaccines.

Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine. Through strategic acquisitions, Takeda has been transforming itself, broadening its therapeutic expertise and geographic outreach.

Additional information about Takeda is available through its corporate website, http://www.takeda.com.

About Sunovion Pharmaceuticals Inc.

Sunovion Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of Sumitomo Dainippon Pharma, and is headquartered in Marlborough, Mass. Sunovion is a leading pharmaceutical company dedicated to discovering, developing and commercialising therapeutic products that advance the science of medicine and improve the lives of patients and their families. More information about Sunovion Pharmaceuticals Inc. is available at http://www.sunovion.com.

References

1. Citrome L et al. Effects of lurasidone on hostility in patients with an acute exacerbation of schizophrenia: a pooled post hoc analysis of 5 short-term studies. EPA 2015. Abstract: 0249

2. Inamdar I et al. Long-term lurasidone treatment is not associated with clinically significant elevations of prolactin- or hyperprolactinaemia-related adverse events: a post-hoc study. EPA 2015. Abstract: 1723

3. Palma dos Reis R et al. Lurasidone and sexual dysfunction: post-hoc analysis of pooled data. EPA 2015. Abstract: 1721

4. Werner P et al. In vitro receptor binding profile of lurasidone and other commonly used Antipsychotics. Eur Neuropsychopharmacol 2012;22(Suppl 2):S349

5. Ishibashi T et al. Pharmacological Profile of Lurasidone, a Novel Antipsychotic Agent with Potent 5-Hydroxytryptamine 7 (5-HT7) and 5-HT1A Receptor Activity. J Pharmacol Exp Ther 2010;334:171-81

6. Healy D et al. Mortality in schizophrenia and related psychoses: data from two cohorts, 1875-1924 and 1994-2010BMJ Open 2012;2:e001810

7. Tiihonen J et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009; 374:620-7

8. De Hert M et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2012;8:114-26.

9. Lewis DA and Lieberman JA. Catching Up on Schizophrenia: Review Natural History and Neurobiology. Neuron 2000;28:325-34

10. Faries DE et al. Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia. BMC Psych 2009; 9:54

11. Tsutsumi C et al. The evolution of antipsychotic switch and polypharmacy in natural practice - A longitudinal perspective. Schizophr Res 2011; 130:40-6

12. Salize HJ et al. Cost of schizophrenia in six European countries. Schizophr Res 2009; 111(1-3):70-7

13. Mangalore R et al. Cost of schizophrenia in England. J Ment Health Policy Econ 2007; 10(1): 23-41

14. Zeidler J et al. The costs of schizophrenia and predictors of hospitalisation from the statutory health insurance perspective. Health Econ Rev 2012; 2(1):9

Date of preparation: March 2015

Job number: GLO/LUR/2015-00038

CONTACT: Media Contacts: Patrick Gaffey, Corporate Communications,Sunovion Pharmaceuticals Inc., +1-508-357-7500,patrick.gaffey@sunovion.com; Elissa Johnsen, Director, ProductCommunications, Takeda Pharmaceuticals, +1-224-554-3185,elissa.johnsen@takeda.com